Unit costs for the treatment of CIN2/3 in each country are shown in Table 2. Costs were expressed in local currency and updated to 2011 value using the country-specific Consumer Price Index reported by the World Bank for each country [20]. Fig. 1 presents country level results grouped by WHO continent

and worldwide of the estimated annual numbers of CC cases potentially avoided by HPV vaccination at steady-state at varying levels of vaccination coverage. Individual country estimates at four levels of vaccination coverage (50, 70, 90 and 100%) are shown in Supplementary File 1. In all five WHO continents, numbers of cases potentially www.selleckchem.com/products/epacadostat-incb024360.html prevented by vaccination was at least 18% greater in the analyses including cases causally related to HPV irrespective of type, compared with the cases causally related to HPV-16/18 infection only. The relative difference (i.e. the percentage increase of cases avoided causally related

Erlotinib in vitro to all HPV types vs. HPV-16/18 only) was most pronounced in Africa (34%). Relative increase of number of cases avoided for other WHO continents was 27% for America, 26% for Asia, 21% for Europe, 18% for Oceania and 27% worldwide. A similar pattern was observed for the estimated annual numbers of CC deaths potentially prevented by HPV vaccination (Fig. 2). Similarly to CC cases prevented, the inclusion of CC deaths prevented irrespective and of HPV type in the analysis increased by at least 18% the estimated number of deaths potentially avoided, with the relative difference having the same values as for CC cases analysis. Individual country estimates

for the CC deaths potentially prevented at four levels of vaccination coverage (50, 70, 90 and 100%) are shown in Supplementary File 2. Table 3 shows the estimated annual cost-offset associated with CC prevention at steady-state in Mexico, Canada, Germany, Thailand and South African Republic. Including VE irrespective of HPV type in the analysis increased the estimated cost-offset in all five countries by at least 10 million Int$. Table 4 presents the estimated annual numbers of CIN2/3 cases avoided by HPV vaccination at steady-state in Italy and Malaysia. The estimated vaccine impact on CIN2/3 cases, and treatment costs averted were 33 and 53% higher in Italy and Malaysia respectively, for the analysis irrespective of HPV type, compared with the estimates for HPV-16/18 only. The results presented here suggest that HPV vaccination of young girls naïve to HPV with the AS04-adjuvanted HPV-16/18 vaccine could reduce the number of CC cases and deaths in countries worldwide, with the absolute number of CC cases and deaths and hence, lives saved depending on the vaccination coverage achieved.